Avaliou-se os efeitos dos ácidos oleanólico (AO) e ursólico (AU), triterpenóides presentes em alimentos vegetais e especiarias, quando administrados a ratos F344 durante as etapas de iniciação e seleção/promoção do modelo de hepatocarcinogênese do \"hepatócito resistente\" (RH). Os ratos receberam durante 8 semanas, por entubação gástrica e dissolvido em óleo de milho (OM): AO ou AU (8 mg/100 g de peso corpóreo [p.c.]). Os grupos controle receberam apenas OM (0,25 mL/100 g de p.c; grupo OM), ou água (0,25 mL/100 g de p.c.; grupo Água). O grupo Normal não recebeu qualquer tratamento. O agente iniciante foi uma dose de dietilnitrosamina (DEN, 20 mg/100 g de p.c.). Após 2 semanas de entubação, aplicou-se 3 doses diárias consecutivas de 2-acetilaminofluoreno (2-AAF) (2 mg/100 g de p.c.) e fez-se uma hepatectomia parcial a 70%, acrescida de 1 dose de 2-AAF (0,5 mg/100 g de p.c.) 4 dias após a cirurgia. Em 6 semanas após a iniciação, os animais foram sacrificados. Resultados: A análise macroscópica demonstrou que AO não determinou alterações e AU tendeu a aumentar o número de nódulos de hepatócitos, comparados ao grupo OM. A análise morfométrica das lesões pré-neoplásicas (LPN) hepáticas positivas para glutationa S-transferase forma placentária (GST-p), demonstrou que AO e AU não determinaram alterações no número médio de LPN persistentes, porém reduziram o número médio de LPN em remodelação, comparados ao grupo OM (p < 0,05). AO e AU não determinaram alterações na área média das LPN persistentes, mas diminuíram a área média das LPN em remodelação, comparados ao grupo OM (p < 0,05). AO e AU não determinaram alterações na área do corte ocupada por LPN persistentes, mas diminuíram a área do corte ocupada por LPN em remodelação, comparados ao grupo OM (p < 0,05). Os grupos Água, OM e AU apresentaram aumento na concentração plasmática de colesterol, comparados ao grupo Normal. AO promoveu aumento da expressão do gene que codifica para a enzima HMG-CoA redutase, comparado ao grupo Normal (p < 0,05), e AU promoveu aumento de expressão quando comparado aos grupos Normal, Água, OM e AU (p < 0,05). AO e AU não determinaram alterações nos índices de proliferação celular (imunoistoquímica para bromodeoxiuridina [BrdU]) nas LPN persistentes. AU promoveu aumento (p < 0,05) na proliferação celular nas LPN em remodelação quando comparado ao grupo OM. AO e AU não determinaram alterações na apoptose em LPN persistentes, mas aumentaram o número médio de corpúsculos apoptóticos nas LPN em remodelação (p < 0,05). O índice de Crescimento Ajustado (apoptose/proliferação celular) dos grupos demonstrou que, nas LPN persistentes, a proliferação celular tem predominância sobre a apoptose. Nas LPN em remodelação, a apoptose tem preponderância sobre a proliferação celular. Os danos no DNA hepático (método do \"cometa\") foram maiores no grupo AO (p < 0,05) e AU (p = 0,061), comparados ao grupo OM. A análise por \"imunoblot\" revelou que o modelo do \"RH\" aumentou a expressão e a ativação do fator de transcrição NF-&#954;B (p < 0,05). AO e AU aumentaram a expressão e a ativação de NF-&#954;B, comparados ao grupo OM (p > 0,05). Observou-se que a proteína supressora de tumor p53 está acumulada no citoplasma dos hepatócitos de 77,2% (Água), 66,5% (OM), 69,6% (AO) e 69,7% (AU) das LPN persistentes, e de 22,8% (Água), 33,5% (OM), 30,4% (AO) e 30,3% (AU) das LPN em remodelação marcadas para p53. A proteína anti-apoptótica bcl-2 apresentou aumento de expressão em 78,4% (Água), 72,6% (OM), 73,0% (AO) e 70,4% (AU) das LPN persistentes, e de 21,6% (Água), 27,4% (OM), 27,0% (AO) e 29,6% (AU) das LPN em remodelação marcadas para bcl-2. Conclusões: AO e AU não apresentaram atividade quimiopreventiva nas condições de estudo, mas diminuíram as LPN em remodelação. O aumento da apoptose e diminuição da proliferação celular estão envolvidos com a remodelação. O fator de transcrição NF-&#954;B está envolvido com a hepatocarcinogênese. AO e AU aumentaram a expressão e a ativação de NF-&#954;B. O acúmulo de p53 no citoplasma, bem como a expressão aumentada de bcl-2 estão relacionados ao fenótipo das LPN persistentes. / It was evaluated the effects of the oleanólico acid (OA) and ursolic acid (UA), triterpenoids present in vegetable foods and spices, when administered to rat F344 during the initiation and selection/promotion stages of the resistant hepatocyte model of hepatocarcinogenesis RH. The rat received for 8 weeks, by gavage and dissolved in com oil (CO): OA or UA (8 mg/100 g of body weight [b.w.]). The control groups just received CO (0,25 mL/100 g b.w.; CO group), or water (0,25 mL/100 g b.w.; group Water). Normal group did not receive any treatment type. The initiation agent was dietilnitrosamine (DEN, 20 mg/100 g b.w.). 2 weeks after gavage, it was applied 3 consecutive doses of 2-acetilaminofluoreno (2-AAF) (2 mg/100 g of b.w.) and it was made a 70% partial hepatectomy, added of 1 dose of 2-AAF (0,5 mg/100 9 b.w.) 4 days after the surgery. In 6 weeks after the initiation, the animals were sacrificed. Results: the macroscopic analysis demonstrated that OA did not alter and UA tended to increase the number of hepatocytes nodules, compared to the CO group. The morphometric analysis of the pre-neoplastic lesions (PNL) positive for glutatione S-transferase placentary form (GST-p), demonstrated that OA and UA did not alter the medium number of persistent LPN, however they reduced the medium number of remodeling LPN, compared to the OM group (p <0,05). OA and UA did not alter the medium area of persistent LPN, but they reduced the medium area of remodeling LPN, compared to the CO group (p <0,05). The triterpenoids did not alter the occupied area of the section for persistent LPN, but they reduced the occupied area cut for remodeling LPN, compared to the CO group (p <0,05). The Water, OM and AU groups showed increase in the plasmatic concentration of cholesterol, compared to the Normal group. OA promoted increase of the expression of the gene that codifies for the HMG-CoA reductase enzyme, compared to the Normal group (p <0,05), and AU promoted increase expression when compared to the Normal, Water, OM and AU groups (p <0,05). OA and UA did not alter the indexes of cellular proliferation (imunoistochemistry for bromodeoxiuridine [BrdU)) in persistent LPN. AU promoted increase (p <0,05) in the cellular proliferation in remodeling LPN when compared to the CO group. OA and UA did not alter the apoptosis in persistent LPN, but they increased the medium number of apoptotics bodies in remodeling LPN (p <0,05). The Adjusted Index Growth (cellular apoptosis/proliferation) of the groups demonstrated that, in persistent LPN, the cellular proliferation has predominance on the apoptosis. In remodeling LPN, the apoptosis has preponderance over the cellular proliferation. The damages in hepatic DNA (method of the \"comet\") were larger in the group OA (p <0,05) and AU (p <0,061), compared to the CO group. The analysis for imunoblot revealed that the RH model increased the expression and the activation of the NF-&#954;B transcription factor (p <0,05). OA and UA increased the expression and the activation of NF-&#954;B, compared to the CO group (p> 0,05). It was observed that the p53 tumor suppresser protein is accumulated in the hepatocytes cytoplasm of 77,2% (Water), 66,5% (CO), 69,6% (OA) and 69,7% (UA) of persistent LPN, and of 22,8% (Water), 33,5% (CO), 30,4% (OA) and 30,3% (UA) of remodeling LPN marked for p53. The bcl-2 anti-apoptotic protein presented increase expression in 78,4% (Water), 72,6% (CO), 73,0% (OA) and 70,4% (UA) of persistent LPN, and of 21,6% (Water), 27,4% (CO), 27,0% (OA) and 29,6% (UA) of remodeling LPN marked for bcl-2. Conclusions: AO and AU did not present chemopreventive activity in the study conditions, but they reduced remodeling PNL. The apoptosis increase and cellular proliferation decrease are involved with the remodeling. The transcription factor NF-&#954;B is involved with the hepatocarcinogenesis. AO and AU increased the expression and the activation of NF-&#954;B. The p53 accumulation in the cytoplasm, as well as the increased expression of bcl-2 is related to the phenotype of persistent PNL.

In my graduation thesis I first of all shortly mentioned frequency–selection filters and their utilisations. However, the base point of this project was to acquaint with different types of signal flow diagrams with whom I should design and analyse frequency-selection filtres with conventional and also innovative active components. As the first I created signal flow diagrams for both voltage and current conveyors. These modern active components are well known today and enable the construction of circuits with better properties than circuits with traditional differentiating amplifiers with voltage feedback. Thereinafter I made signal flow diagrams for OTA component. Transconductancal amplifiers are well known active components used in various areas of analog signal processing. OTA amplifier is in fact the current source controlled by voltage difference, which is characterised by gm transconductance. Ulterior components were IOZ and IZN models of voltage amplifier with voltage gain A. The last component was COA amplifier. It is a current operational amplifier. COA model is fully dual component to VOA, which is classical voltage amplifier. In my project I used filters with two OTA components. This filter offers functions like low-pass filter, band-pass filter, high-pass filter, band-stop filter and two-phase network. Following this I used circuits with two GCC conveyors. These offer band-pass filter, low-pass filter, high-pass filter, band-stop filter and two-phase network. Ultimately I designed filters with COA components, which offer three transmission functions simultaneously (DP, PP and HP). Analysis of these filters was made with a help of PSpice computer programme.

In der vorliegenden Arbeit werden zwei Enzymsysteme – Ni-haltige Kohlenmonoxid-Dehydrogenase (CODH) und [NiFe]-haltige Hydrogenase – strukturell untersucht. Im 1. Teil werden die Untersuchungen des ACDS-Komplexes aus A. fulgidus mittels Transmissionselektronenmikroskopie (Negativkontrastierung und der Kryo-Einbettung) geschildert. Die 3D-Rekonstruktion mit einer Auflösung von 29 Å wird de novo ermittelt und drei mögliche Positionen für die CODH-Untereinheit vorgeschlagen. Im 2. Teil wird die Röntgenkristallstrukturanalyse der CODH-Untereinheit des ACDS Komplexes aus A. fulgidus geschildert. Das Protein besteht aus α- und ε-Untereinheiten, die zusammen eine α2ε2-Stöchiometrie bilden (Afα2ε). Während die Gesamtstruktur von Afα2ε2 jener von M. barkeri (Mbα2ε2) ähnelt, führt der Austausch der koordinierenden Cys zu Asp und Glu zu einer Deletion des verbrückenden FeS-Zentrums. Die Rolle der ε-Untereinheit wird durch kinetische Studien untersucht. Die CO-abhängige FAD-Reduktionsaktivität von Afα2ε2 folgt einer Michaelis-Menten Kinetik. Die Mbα2ε2 hat ein ähnliches Kinetikverhalten. Im Gegensatz dazu weist die CODH-II von C. hydrogenoformans, die keine ε-Untereinheit hat, eine lineare Abhängigkeit der CO-abhängigen FAD-Reduktionsaktivität von Flavin auf. Diese Beobachtungen sind im Einklang mit der Annahme, dass die ε-Untereinheit ein Gerüst für die Flavinbindung bereitstellt. Der 3. Teil ist der F420-reduzierenden Hydrogenase aus M. barkeri (MbFRH) gewidmet. Die Struktur von MbFRH wird mittels Röntgenkristallographie bestimmt und ergibt eine dodekamerische Anordnung von ca. 1.2 MDa. Zusammen mit der etablierten Elektronenübertragungskette, beobachtet in FRH aus M. marburgensis, wird in MbFRH auch ein [2Fe2S]-Cluster und eine Fe-Stelle detektiert. Schließlich führen die schwingungsspektroskopischen Analysen zusammen mit der Röntgenkristallographie zu dem Schluss, dass MbFRH in einem bisher strukturell nicht charakterisierten, katalytisch aktiven Nia-S Zustand isoliert wird. / In this work, we structurally characterize two metal-based enzyme systems from archaea: Ni-containing CO dehydrogenase (CODH) and [NiFe] containing hydrogenase. In the first chapter we investigate, using transmission electron microscopy, the ACDS complex from A. fulgidus (AfACDS). The purified ACDS complex can be visualized as an intact globular protein particle by negative stain and vitrification techniques. The 3D reconstruction is determined de novo to 29 Å-resolution by single-particle analysis. We suggest three possible positions for the CODH subunit within ACDS by rigid-body fitting. In the second chapter we determine the X-ray crystal structure of the CODH subunit. The 220 kDa protein is composed of α- and ε-subunits that form a heterodimer with (α2ε2) stoichiometry (Afα2ε2). While the overall structure of Afα2ε2 resembles the previously reported structure of the α2ε2-subunit from M. barkeri (Mbα2ε2), the naturally-occurring exchange of the Cys to Asp and Glu results in a depletion of the bridging iron-sulfur cluster. The role of the ε-subunit is investigated by kinetics studies. CO-dependent FAD reduction activity of Afα2ε2 exhibits Michaelis-Menten type kinetics. The same kinetic type is demonstrated for the Mbα2ε2-subunit. In contrast, the ε-subunit lacking CODH-II from C. hydrogenoformans shows linear dependency between CO-dependent FAD reduction activity and flavin concentration. The data suggests that the ε-subunit provides a scaffold for the flavin binding. In the third chapter we study the F420-reducing hydrogenase from M. barkeri (MbFRH). Its structure is solved by X-ray crystallography, revealing a dodecameric arrangement of 1.2 MDa. Along with the established ET chain observed in FRH from M. marburgensis, one solvent-exposed [2Fe2S] cluster and an additional Fe metal site are detected. The combined approach of X-ray crystallography and vibrational spectroscopy reveals that MbFRH is isolated in the previously structurally uncharacterized Nia-S state.

During the last several decades, many people, fleeing from disasters or political threats, have applied for asylum in the European countries. Council Directive 2003/9/EC, laying down minimum standards for the reception of asylum-seekers, as well as several other directives, have been developed in the EU in order to ensure fair treatment of the asylum-seekers in all the European countries. However, there are huge differences in the national asylum laws of countries and consequently, the way they treat the asylum-seekers. In this research, the national asylum laws of Germany and the Netherlands are studied and compared, showing that though following the Council Directive, fair or equal treatment of asylum-seekers cannot be guaranteed. In the Netherlands asylum-seekers are granted with a great extent of benefits while in Germany, they are greatly discriminated against. Based on the Social Determinants of Health Model, developed by Dahlgren and Whitehead in 1991, the hypothesis is that the asylum seekers in the Netherlands enjoy better health status than the ones in Germany, because based on the Dutch asylum laws, they have better living and working conditions. In order to confirm or negate this hypothesis, a meta-study of available literature on the health status of asylum-seekers has been done. However, the hypothesis could not be confirmed/ negated due to extreme lack of availability of data in this area. By discussing the relationship between life conditions and health of individuals, reviewing current legal instruments regulating asylum in the EU and analyzing the available data on the health status of asylum-seekers, this paper draws the attention to the importance of data and research on these topics and the need for development of practices for collection of such information. Availability of such information can affect future decision and policy makings regarding asylum-seekers and their health and might result in comprehensive reformations in the current national or international legal instruments.

<p>Problem – The expansion of global trade and supply chain integration has put great emphasison logistics, particularly in the intermediary sector, freight forwarders. Whilst in developedcountries freight forwarders benefit from competitive markets and trade facilitatingpolicies, this sector in West coast Africa exhibits low logistics performance levels. Inorder to address such issues, one needs to analyse the problem and identify the causes; thisthesis focuses on identifying the bottlenecks in the freight-forwarding sector in west coastAfrica.Purpose – The main purpose of this study is to identify the bottleneck/s within thefreight-forwarding industry in west coast Africa, namely: Angola, Cameroon, DR of Congo,Gabon, and Nigeria.Method – This thesis employs a pre-study and case study method, to ensure sufficient collectionof relevant material, taking into account the lack of research in this subject. We usedthe material obtained from the interviews and the secondary source, to structure our purpose,research questions, and to define the case of our study.Results – The study concludes with a series of interesting findings; First, the activity of aFreight Forwarder depends on a series of factors that do not depend on the Freight Forwarderper se. And second, Freight Forwarders in order to accomplish their tasks, have accessto services that are shared by all providers, and that are beyond their control. To conclude,the study identifies infrastructure as a major bottleneck in the Freight Forwarding sector.</p>

Background: Recent evidence suggests that the prostate cancer (PCa)-specific up-regulation of certain genes such as AMACR, EZH2, PSGR, PSMA and TRPM8 could be associated with an aberrant expression of non-coding microRNAs (miRNA). Methods: In silico analyses were used to search for miRNAs being putative regulators of PCa-associated genes. The expression of nine selected miRNAs (hsa-miR-101, -138, -186, -224, -26a, -26b, -374a, -410, -660) as well as of the aforementioned PCa-associated genes was analyzed by quantitative PCR using 50 malignant (Tu) and matched non-malignant (Tf) tissue samples from prostatectomy specimens as well as 30 samples from patients with benign prostatic hyperplasia (BPH). Then, correlations between paired miRNA and target gene expression levels were analyzed. Furthermore, the effect of exogenously administered miR-26a on selected target genes was determined by quantitative PCR and Western Blot in various PCa cell lines. A luciferase reporter assay was used for target validation. Results: The expression of all selected miRNAs was decreased in PCa tissue samples compared to either control group (Tu vs Tf: -1.35 to -5.61-fold; Tu vs BPH: -1.17 to -5.49-fold). The down-regulation of most miRNAs inversely correlated with an up-regulation of their putative target genes with Spearman correlation coefficients ranging from -0.107 to -0.551. MiR-186 showed a significantly diminished expression in patients with non-organ confined PCa and initial metastases. Furthermore, over-expression of miR-26a reduced the mRNA and protein expression of its potential target gene AMACR in vitro. Using the luciferase reporter assay AMACR was validated as new target for miR-26a. Conclusions: The findings of this study indicate that the expression of specific miRNAs is decreased in PCa and inversely correlates with the up-regulation of their putative target genes. Consequently, miRNAs could contribute to oncogenesis and progression of PCa via an altered miRNA-target gene-interaction.

Les données épidémiologiques montrent une association inverse entre les taux de HDL-cholestérol (HDL-C) et le risque d'évènements cardiovasculaires. Des traitements ayant montré une augmentation significative du HDL-C, comme les inhibiteurs de la protéine de transfert des esters de cholestérol, devraient donc permettre de réduire le risque cardio-vasculaire. En utilisant différentes techniques de modélisation, nous avons tenté de quantifier l'efficacité attendue sur les événements cardiovasculaires de l'un d'entre eux, le dalcétrapib, ne disposant que de données pharmacocinétiques et pharmacodynamiques. Tout d'abord, afin d'établir la relation pharmacocinétique / pharmacodynamique entre les concentrations et la modification de HDL-C, nous avons analysé les données individuelles des patients dyslipidémiques par une approche de population. Une hausse moyenne de HDL-C de 26.4 % par rapport au placebo était alors anticipée. Nous avons ensuite tenté de corréler l'effet observé sur l'HDL-C et l'effet clinique à partir de données d'autres études par méta-régression des essais évaluant l'effet des principaux hypolipémiants en prévention secondaire. Cette modélisation n'a pas permis de montrer de corrélation entre le changement de l'HDL-C (P5 P95 :-3.0 et 36 %) et la réduction du risque cardiovasculaire. Une analyse de sensibilité par type de traitement suggère qu'une même hausse de HDL-C entre deux classes thérapeutiques pourrait se traduire par un effet clinique dissemblable, indiquant que HDL-C ne peut pas être utilisé comme critère intermédiaire puisqu'il ne serait pas un prédicteur indépendant du risque cardiovasculaire

Les sécrétines de l’hormone de croissance (GHRPs) sont de petits peptides synthétiques capables de stimuler la sécrétion de l’hormone de croissance à partir de l’hypophyse via leur liaison au récepteur de la ghréline GHS-R1a. Le GHRP hexaréline a été utilisé afin d’étudier la distribution tissulaire de GHS-R1a et son effet GH-indépendant. Ainsi, par cette approche, il a été déterminé que l’hexaréline était capable de se lier à un deuxième récepteur identifié comme étant le récepteur scavenger CD36. Ce récepteur possède une multitude de ligands dont les particules oxLDL et les acides gras à longue chaîne. CD36 est généralement reconnu pour son rôle dans l’athérogénèse et sa contribution à la formation de cellules spumeuses suite à l’internalisation des oxLDL dans les macrophages/monocytes. Auparavant, nous avions démontré que le traitement des macrophages avec l’hexaréline menait à l’activation de PPARƔ via sa liaison à GHS-R1a, mais aussi à CD36. De plus, une cascade d’activation impliquant LXRα et les transporteurs ABC provoquait également une augmentation de l’efflux du cholestérol. Une stimulation de la voie du transport inverse du cholestérol vers les particules HDL entraînait donc une diminution de l’engorgement des macrophages de lipides et la formation de cellules spumeuses. Puisque CD36 est exprimé dans de multiples tissus et qu’il est également responsable du captage des acides gras à longue chaîne, nous avons voulu étudier l’impact de l’hexaréline uniquement à travers sa liaison à CD36. Dans le but d’approfondir nos connaissances sur la régulation du métabolisme des lipides par CD36, nous avons choisi des types cellulaires jouant un rôle important dans l’homéostasie lipidique n’exprimant pas GHS-R1a, soient les adipocytes et les hépatocytes. L’ensemble de mes travaux démontre qu’en réponse à son interaction avec l’hexaréline, CD36 a le potentiel de réduire le contenu lipidique des adipocytes et des hépatocytes. Dans les cellules adipeuses, l'hexaréline augmente l’expression de plusieurs gènes impliqués dans la mobilisation et l’oxydation des acides gras, et induit également l’expression des marqueurs thermogéniques PGC-1α et UCP-1. De même, hexaréline augmente l’expression des gènes impliqués dans la biogenèse mitochondriale, un effet accompagné de changements morphologiques des mitochondries; des caractéristiques observées dans les types cellulaires ayant une grande capacité oxydative. Ces résultats démontrent que les adipocytes blancs traités avec hexaréline ont la capacité de se transformer en un phénotype similaire aux adipocytes bruns ayant l’habileté de brûler les acides gras plutôt que de les emmagasiner. Cet effet est également observé dans les tissus adipeux de souris et est dépendant de la présence de CD36. Dans les hépatocytes, nous avons démontré le potentiel de CD36 à moduler le métabolisme du cholestérol. En réponse au traitement des cellules avec hexaréline, une phosphorylation rapide de LKB1 et de l’AMPK est suivie d’une phosphorylation inhibitrice de l’HMG-CoA réductase (HMGR), l’enzyme clé dans la synthèse du cholestérol. De plus, la liaison d'hexaréline à CD36 provoque le recrutement d’insig-2 à HMGR, l’étape d’engagement dans sa dégradation. La dégradation de HMGR par hexaréline semble être dépendante de l’activité de PPARƔ et de l’AMPK. Dans le but d’élucider le mécanisme d’activation par hexaréline, nous avons démontré d’une part que sa liaison à CD36 provoque une déphosphorylation de Erk soulevant ainsi l’inhibition que celui-ci exerce sur PPARƔ et d’autre part, un recrutement de l’AMPK à PGC-1α expliquant ainsi une partie du mécanisme d’activation de PPARƔ par hexaréline. Les résultats générés dans cette thèse ont permis d’élucider de nouveaux mécanismes d’action de CD36 et d'approfondir nos connaissances de son influence dans la régulation du métabolisme des lipides. / Growth hormone releasing peptides (GHRPs) are small synthetic peptides aimed at stimulating GH release from the pituitary through their binding to ghrelin receptor known as growth hormone secretagogue receptor 1a (GHS-R1a). Using the GHRP, hexarelin to study tissue distribution of GHS-R1a and its GH-independent effect, it was observed that hexarelin was capable of binding to a second receptor identified as scavenger receptor CD36. While having multiple ligands, CD36 is mainly known for binding and internalizing oxLDL and long chain fatty acids. CD36 is thought to play a detrimental role in macrophage derived foam cell formation and development of atherosclerosis. Previously, we have shown that in macrophages, expressing both GHS-R1a and CD36, hexarelin promoted an activation of PPARƔ via GHS-R1a but also through its binding to CD36. This activation led to the induction of the LXRα-ABC transporters pathway and an increase in cholesterol efflux, reducing lipid-laden macrophage content. This positive effect on macrophages was reproduced in apolipoprotein E-null mice on a high fat diet treated with hexarelin. A significant reduction in the size of atherosclerotic lesions was observed while similar increases in the expression of PPARƔ, LXRα and ABC transporters occurred in isolated peritoneal macrophages. CD36 also plays a role in fatty acid uptake, and to further investigate the impact of the interaction of hexarelin with CD36, we aimed at evaluating the role of CD36 in regulating lipid metabolism in cells devoid of GHS-R1a such as adipocytes and hepatocytes. In the present thesis, we demonstrated through its interaction with hexarelin, the ability of CD36 to decrease intracellular lipid content in both adipocytes and hepatocytes. In adipocytes, hexarelin was able to increase the expression of several genes involved in fatty acid mobilization, fatty acid oxidation but also to induce the expression of the thermogenic markers, PGC-1α and UCP-1. In addition, hexarelin increased the expression of genes involved in mitochondrial biogenesis which was accompanied by mitochondrial morphological changes in agreement with what is usually seen in highly oxidative cells. In support of these findings, we also observed an increase in the activity of cytochrome c oxidase (a component of the respiratory chain) which could reflect an increase in oxidative phosphorylation. The results generated with cultured white adipocytes suggest the ability of hexarelin to promote changes toward a brown fat-like phenotype which also occurred in vivo and was dependent on the presence of CD36. In hepatocytes, CD36 was capable of regulating cholesterol metabolism by rapidly phosphorylating LKB1 and AMPK which subsequently resulted in the inactivating phosphorylation of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. Hexarelin via CD36 also induced the recruitment of insig-2 to HMGR, the committed step in HMGR degradation while lifting the exerted inhibitory effect of Erk on nuclear receptor PPARƔ activity, and promoting the recruitment of AMPK to PPARƔ coactivator PGC-1α, suggesting an enhanced transcriptional potential of PPARƔ. The results generated during my graduate studies represent unique and novel mechanisms by which CD36 is capable of regulating lipid metabolism.

Clinical evidence suggested patients with lower plasma C-reactive protein (CRP) levels after statin therapy could have better clinical outcome. The last part of the study was to measure on-treatment high sensitivity CRP (hsCRP) levels among 229 Chinese patients with hyperlipidaemia undergoing treatment with simvastatin 40 mg daily. The patients were genotyped for 15 SNPs or haplotypes in 11 candidate genes that would have significant allele frequency among Chinese patients and may be linked to statin efficacy or hsCRP levels. The analysis suggested BMI is the largest single contributing factor of 15.0% of the variation in hsCRP levels, followed by plasma triglycerides levels contributing 4.7% and male gender 1.6% (all P&lt;0.05). However comparisons of hsCRP levels among genotype groups did not reveal any significant findings, with or without adjustment with covariate genotypic or phenotypic factors. To further categorize individuals as high or medium risk, we set a threshold hsCRP level of 1 mg/L as the benchmark for evaluation. The CRPc.3872G>A SNP was related to lower risk compared to the homozygous wild-type genotype (adjusted odds ratio AOR = 0.289; P = 0.014) after adjusting for phenotypic factors of age, gender, smoking status, BMI, waist circumference, hip circumference, plasma lipid profiles, co-existing disease and co-medications. Another marginal finding included the HNF1A c.79A>C SNP (AOR = 0.575; P = 0.118). / Polymorphisms in the drug transporters are likely to be more important with hydrophilic statins such as pitavastatin, which undergoes transporter mediated distribution. The SLCO1B1 c.388A>G polymorphism in the gene encoding the uptake transporter organic anion transporting polypeptide (OATP1B1) is common in Chinese and the variant was associated with increases of 63--68% in maximum plasma concentration and 44--47% in systemic exposure of both the lactone and acid compared to wild-type subjects (P&lt;0.05). Co-administration of pitavastatin with grapefruit juice (GFJ) resulted in a small increase of the area under the plasma concentration time curve (AVC) by 15--16% for both the acid and lactone (P&lt;0.05). However, there was no significant effect on the drug-food interaction in relation to relevant SNPs in the enzymes and transporters examined. / The SNPs examined included those in the genes for the enzymes and transporters involved in the metabolic pathway or the distribution of simvastatin. Cytochrome P450 (CYP) enzymes are involved in hepatic and intestinal metabolism of several statins and simvastatin is known to undergo extensive metabolism via the CYP3A4/3A5 pathway. The common candidate SNPs in the CYP3A4/3A5 enzymes found in Chinese populations include CYP3A4*1G, CYP3AP1*3 and CYP3A5*3 , which are associated with altered enzyme expression and activity. However, no statistically significant relationship was found between these SNPs and a potential phenotypic marker of enzyme activity, the urinary ratio of 6beta-hydroxy-cortisol/cortisol (6beta-OHC/C) concentrations. The analysis of lipid lowering responses in relation to individual SNPs or combinations from gene-gene interactions also revealed no statistically significant findings. In the subgroup of patients with familial hypercholesterolaemia, the CYP3A4*1G, CYP3AP1*3 and CYP3A5*3 polymorphisms appeared to have a small effect on the changes in LDL-C and total cholesterol with the subjects with the CYP3A5*3 and CYP3AP1*3 variants showing less reduction and those with the CYP3A4*1G variant showing more reduction than subjects with the wild-type genotype with a tendency for a gene-dose effect. It is difficult to interpret these findings and the significance may be related to multiple testing. / The statins, or 3-hydroxymethyl-3-glutaryl coenzyme A (HMG-CoA) reductase inhibitors, act on the rate limiting step in endogenous cholesterol synthesis. Their primary action results in reduction of plasma low-density lipoprotein cholesterol (LDL-C) levels and this is thought to be the major mechanism by which they reduce cardiovascular events. There are considerable differences between subjects in both the plasma levels of the statins and in their effects on LDL-C and other lipid parameters and some of this variation appears to be related to genetic differences in the pathways of drug metabolism and distribution and in the pathways involved in lipid metabolism. / The variation in response may be related to variations in systemic or hepatic exposure to the drug, which in turn will be related to the pharmacokinetics. This is also likely to play a role in the adverse effects of myopathy and therapeutic tolerance. In a pharmacokinetic study in healthy male Chinese subjects, the common polymorphism of CYP2D6*10 was analyzed in relation to the pharmacokinetics of lovastatin and simvastatin. There was a tendency for reduced clearance of simvastatin lactone by 30% (P>0.05) in subjects with the CYP2D6*10/*10 genotype. With lovastatin, there were similar findings with 38.5--84.9% decrease in clearance which appeared to be related to enzyme activity according to genotype, with *5 carriers showing a greater decline in clearance than *10 carriers (P&lt;0.05). / These results provide some insights into the pharmacokinetics and pharmacodynamics of statins and the pharamacogenetic relationships to candidate SNPs. Future research in this field should help to facilitate safer and more effective treatment with these commonly used medications, resulting in personalized therapy and optimal clinical benefits for patients with cardiovascular disease. / This thesis describes a study of 270 patients recruited from the outpatient clinics at the Prince of Wales Hospital who were treated with simvastatin 40 mg daily for at least 4 weeks. Their mean (+/-SD) LDL-C baseline level was 5.38+/-1.68 mmol/L and the reduction in LDL-C after simvastatin treatment was 2.81+/-0.99 mmol/L or -47.1+/-12.5%. / Mak, Wah Lun Valiant. / Adviser: Brian Tomlinson. / Source: Dissertation Abstracts International, Volume: 73-06, Section: B, page: . / Thesis (Ph.D.)--Chinese University of Hong Kong, 2011. / Includes bibliographical references (leaves 253-289). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Electronic reproduction. [Ann Arbor, MI] : ProQuest Information and Learning, [201-] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstract also in Chinese.

<p>The development of the metabolic syndrome (MetS) and cardiovascular diseases have been suggested to be influenced more by the quality than the amount of dietary fat. The FA composition of serum lipids may be used as biomarkers of dietary fat quality. FAs can, however, also be endogenously synthesized by lipogenic enzymes such as elongases and desaturases. Three desaturases are important in humans: Stearoyl-CoA-desaturase (SCD), ∆6-desaturase (D6D) and ∆5-desaturase (D5D) and surrogate measures of desaturase activities can be estimated as product-to-precursor FA ratios.</p><p>In this thesis, we demonstrated that high SCD, D6D and low D5D estimated activities predicted MetS 20 years later, as well as cardiovascular and total mortality during a maximum of 33.7 years. The relation between D5D and MetS was independent of lifestyle and BMI, while the relation between SCD, D6D and MetS was confounded by BMI. Serum proportions of palmitic (16:0), palmitoleic (16:1) and dihomo-γ-linoleic acids were higher and the serum proportion of linoleic acid (LA) lower at baseline in those individuals who developed MetS. Further, LA was inversely related to mortality, while palmitic, palmitoleic and dihomo-γ-linoleic acids were directly associated with mortality. We also demonstrated that a diet rich in saturated fat “induced” a similar serum FA pattern (including estimated desaturase activities) that was associated with MetS, cardiovascular disease and mortality. We also propose that the SCD ratio [16:1/16:0] might be a novel and useful marker of dietary saturated fat, at least in Western high-fat diets. Finally, genetic variations in the human SCD1 gene were linked to obesity and insulin sensitivity, results that agree with data in SCD1 deficient mice.</p><p>This thesis suggests that dietary fat quality and endogenous desaturation may play a role in the development of metabolic and cardiovascular diseases and the results support current dietary guidelines.</p>